The hallmark of type 1 diabetes is the irreversible destruction of insulin-secreting β-cells in the pancreas. Consequently, an attractive therapeutic approach is to trigger the regeneration of functional β-cells elsewhere within a diseased individual. We have previously demonstrated that removal of Foxo1 in Neurogenin3 (Ngn3)-expressing cells creates functional insulin-secreting cells within the intestine. The cells, however, only convert into insulin+ cells at a low frequency, limiting their therapeutic potential. Using a novel knock-in reporter mouse that encodes a Foxo1-Venus fusion protein (FoxV), we have identified a novel population of Foxo1-expressing cells in the glandular epithelium of the stomach. These cells are distinct from other gut FoxV+ cells in that, unlike Foxo1+ cells in the intestine, stomach FoxV+ cells rarely express serotonin. To identify the nature of Foxo1+ stomach cells, we next isolated single cells from stomach and, using flow cytometry and qPCR, analyzed the gene expression of FoxV+ cells. Although Foxo1-positive cells do not express markers of chief, pit, or neck cells, they have increased transcript levels of the parietal cell marker H+/K+ ATPase. We further validated these results by immunofluorescence and FACS. To determine if elimination of Foxo1 can convert stomach cells to insulin-producing cells, we next ablated Foxo1 in either Ngn3+ or parietal cells in mice using cre-mediated recombination. Strikingly, we detected cells positive for insulin and C-peptide in the stomach of mice harboring Foxo1 deletion. Similarly, when we inactivated Foxo1 in primary stomach cultures, we detected markedly increased “β-like” gene expression and insulin+, C-peptide+ cells. Taken together we have identified a new population of Foxo1-expressing cells in the stomach and demonstrated that Foxo1 ablation is sufficient to convert these cells to insulin-producing cells.

Disclosure

W. McKimpson: None. T. Kuo: None. D. Accili: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.